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Background: Prognostic indicators for gastrointestinal stromal tumors (GISTs) are under investigation. The latest risk
classification criteria may still have room for improvement. This study aims to investigate prognostic factors for
primary GISTs from three aspects, including clinicopathological parameters, immunohistochemical (IHC) expression
of PTEN, and Ki-67 labeling index (LI), and attempts to find valuable predictors for the malignancy potential of
primary GISTs.
Methods: Tumor samples and clinicopathological data from 84 patients with primary GISTs after R0 resection were
obtained. Immunohistochemical analysis was performed based on tissue microarray (TMA) to estimate expression of
PTEN and Ki-67 in tumor cells.
Results: The cut-off point of Ki-67 LI was determined as 1%, using a receiver operator characteristic test with a
sensitivity of 71.7% and a specificity of 64.5%. Univariate analysis demonstrated the following factors as poor
prognostic indicators for relapse-free survival (RFS) against a median follow-up of 40.25 months: gastrointestinal (GI)
bleeding (P = 0.009), non-gastric tumor location (P = 0.001), large tumor size (P = 0.022), high mitotic index
(P < 0.001), high cellularity (P = 0.012), tumor rupture (P = 0.013), absent or low expression of PTEN (P = 0.036), and
Ki-67 LI >1% (P = 0.043). Gastrointestinal bleeding (hazard ratio, 3.85; 95% confidence interval, 1.63 to 9.10; P = 0.002)
was a negative independent risk predictor in multivariate analysis, in addition to tumor size (P = 0.023), and mitotic
index (P = 0.002). In addition, GI bleeding showed a good ability to predict recurrence potential, when included in
our re-modified risk stratification criteria.
Conclusions: This study suggests that GI bleeding is an independent predictor of poor prognosis for RFS in
primary GISTs. Expression of PTEN and Ki-67 are correlated with high risk potential and may predict early recurrence
in univariate analysis.
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Gastrointestinal stromal tumors (GISTs) constitute the
most common mesenchymal neoplasms of the gastrointes-
tinal (GI) tract, and the incidence has increased significantly
over the past three decades [1,2]. Gain-of-function muta-
tions in c-kit and, less commonly, the platelet derived
growth factor receptor α (PDGFRA) oncogene are believed
to be the driving force of GISTs [3,4]. All GISTs have malig-
nant potential, varying from small lesions to aggressive sar-
comas. Disease relapse is not uncommon, even where
tumors are R0 resected. The application of imatinib mesy-
late (IM), a small-molecule tyrosine kinase inhibitor, has
dramatically promoted the disease-free survival of GISTs.
However, side effects and resistance to IM pose new chal-
lenges in the management of GISTs. Thus, an accurate risk
classification scheme has become increasingly crucial for
selecting patients who are most likely to benefit from adju-
vant IM therapy. National Institutes of Health (NIH) con-
sensus criteria [5], Armed Forces Institute of Pathology
(AFIP) criteria [6], and modified NIH consensus criteria [7]
are used frequently to estimate the risk of recurrence after
surgery in GISTs. However, even the latest risk stratification
system may still have room for improvement.
Most GISTs initially manifest as GI bleeding. We have
noted in clinical practice that patients presenting with
GI bleeding have appeared to fare worse than their
counterparts. Few, if any, studies have addressed the
prognostic implication of this important manifestation
and its correlation with risk classification.
The PTEN (phosphatase and tensin homolog deleted
from chromosome 10) gene is considered ‘the most highly
mutated tumor-suppressor gene in the post-p53 era’ [8].
By dephosphorylating phosphoinositol 3,4,5-triphosphate
(PIP3), PTEN negatively controls the activation of the PI3-
kinase/Akt pathway, which has been found to be a crucial
survival cell signaling transduction in GISTs [9], and thus
functions as a proapoptosis factor. Also, PTEN plays a role
in the control of the cell cycle and cell migration [10,11].
Loss of PTEN protein expression or function has been re-
ported in many human cancers, including ovarian, endo-
metrial, and prostate carcinoma, and breast cancer [12].
Ki-67, a nuclear protein universally expressed among
proliferating cells and absent in quiescent cells [13], is
one of the most frequent biomarkers investigated on
GISTs. Although previous studies have shown that Ki-67
labeling index (LI) could be used in predicting the malig-
nant potential of GISTs [14], conflicting opinions have
challenged whether its expression level provides better
prognostic utility than mitotic rate [15].
By using tissue microarray (TMA)-based immunohis-
tochemistry (IHC), we aimed to analyze the impact of
aforementioned factors, including clinicopathological pa-
rameters, PTEN expression, and Ki-67 LI, on the recur-
rence risk of R0 resected primary GISTs to identifypotential new indicators that might better predict their
clinical behavior and prognosis.
Methods
Patients and specimens
In total, 175 GIST cases, diagnosed and treated between
January 2005 and January 2011, were retrieved from the
hospitalization archives of the clinical medical college of
Yangzhou University/Northern Jiangsu People’s Hospital
(NJPH), Yangzhou, China. Of these patients, 133 received
surgical resection. The inclusion criteria for this study were:
(1) primary localized GISTs with R0 resection; (2) no other
synchronous primary tumors; and (3) preoperative or post-
operative adjuvant treatment (chemotherapy, radiotherapy
and IM) were not given. Of these, 49 patients were ex-
cluded owing to: non-R0 resection (n = 7), receiving adju-
vant treatment (n = 15), having other synchronous tumors
(n = 13), missing clinical data (n = 8) or inadequate material
for histological examination (n = 6). Thus, 84 GIST patients
with full clinicopathological records and adequate formalin-
fixed paraffin-embedded (FFPE) tissue blocks were enrolled
in the current study. The FFPE tumor specimens were
obtained from the archives of the Department of Pathology
at NJPH.
Follow-up
Follow-up information was obtained from medical
charts, the hospital tumor registry, or direct contact with
patients or their family. Recurrence or metastasis was
considered the most suitable event for survival analysis
because overall survival could be biased by the introduc-
tion of IM as a treatment for recurrent and metastatic
GISTs. Relapse-free survival (RFS) was calculated from
the date of surgical resection to the date of GIST recur-
rence or metastasis or to the last follow-up date, if GIST
without recurrence or metastasis.
Clinicopathological parameters
All GISTs were initially diagnosed as GI mesenchymal
(non-epithelial) tumors by H & E staining, and further con-
firmed by positive IHC staining of CD117 or DOG-1, with
or without CD 34, desmin, SMA, or S-100 positive expres-
sion. If the specimen was negative for both CD 117 and
DOG-1, DNA mutation analysis of c-kit gene exons 9, 11,
13, and 17 or PDGFRA gene exons 12 and 18 were
employed. Clinical data including age, sex, initial manifest-
ation, primary tumor site, tumor size, and tumor rupture
(before or during surgery) were obtained from medical re-
cords. Gastrointestinal bleeding was identified by the pres-
ence of hematemesis, black stools, or positive fecal occult
blood, with or without anemia. Tumor size (maximum
diameter) was measured by pathologists before the speci-
men was fixed. Histopathological parameters for analysis
were as follows: predominant cell type (spindle, epithelioid,
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power fields), tumor necrosis, cellularity (paucicellular
(≤25% cells, >75% stroma), moderate (cells vs. stroma bet-
ween 25% and 75%), or high (≥75% cells, <25% stroma)).
Risk stratification was made based on modified NIH con-
sensus criteria encompassing four factors: size, mitotic
index, site, and rupture [7] (Table 1).
Tissue microarray construction
The FFPE tissue blocks and corresponding H & E
stained slides were used for TMA sampling. Two trained
pathologists (XWG and CRZ) reviewed all the H & E
stained slides and selected the most representative areas
of tumor cells for tumor sampling. An MTA-1 manual
tissue arrayer (Beecher Instruments, Sun Prairie, WI,
USA) was used to punch 2.0-mm-diameter cylinders
from each donor block and transfer them to the re-
cipient paraffin block. Four-μm-thick multiple sections
were cut from the TMA using a Leica RM2165 fully
motorized rotary microtome (Leica Instruments GmbH,
Nussloch, Germany), and prepared for subsequent IHC
staining.
Immunohistochemistry staining
The TMA slides were deparaffinized with xylene and dehy-
drated through a series of alcohol solutions. Endogenous
peroxidase was quenched with 0.3% hydrogen for 10 min at
room temperature. Antigen retrieval was performed with
heat-induced methods using EDTA buffer (pH 8.0) for
15 min at 95°C, then cooled at room temperature for
20 min and washed with PBS. After being blocked with 5%
fetal calf serum for 20 min at room temperature, sections
were incubated with primary antibodies in an appropriate
dilution overnight at 4°C. The primary antibodies used in
the study were PTEN (1:50; clone D4.3; #9188P; Rabbit
monoclonal antibody immunoglobulin G (IgG); Cell Signal-
ing Technology, Danvers, MA, USA), which recognizes en-
dogenous levels of total PTEN protein, and Ki-67 (1:200;Table 1 Modified NIH consensus criteria for GISTs risk stratifi
Risk category Tumor size (cm) Mitotic
Very low risk <2.0
Low risk 2.1 to 5.0








5.1 to 10.0clone D2H10; #9027S; Rabbit monoclonal antibody IgG;
Cell Signaling Technology, Danvers, MA, USA), which de-
tects endogenous levels of total Ki-67 protein. After wash-
ing three times in PBS, primary antibodies were detected
using a horseradish peroxidase-labeled polymer (Power-
Vision Poly-HRP anti-Rabbit IgG; Leica Microsystems,
Buffalo Grove, IL, USA) for 30 min at room temperature.
Then 3,3′-diaminobenzedine (DAB) was used to visualize
the antigens. Finally, slides were counterstained with
hematoxylin, dehydrated, and mounted. As negative con-
trols, the primary antibodies were replaced with PBS. The
known positive tissue sections served as positive internal
controls.
Immunohistochemistry assessment
All TMA spots were scanned at a high resolution (20×)
using the Aperio system (Aperio Technologies, Inc., Vista,
CA, USA) and scored manually on computer screen
independently by two pathologists (XWG and CRZ) in a
blinded manner. The scoring of PTEN expression was
based on the intensity and extent of staining and was eva-
luated according to the following histological scoring
method. The mean proportion of staining cells was de-
termined semiquantitatively and scored as follows: 0 for
staining <1%, 1 for 1 to 25%, 2 for 26 to 50%, 3 for 51 to
75%, and 4 for >75% of the examined cells. Staining inten-
sity was graded as follows: 0, negative staining; 1, weak
staining; 2, moderate staining; 3, strong staining. The histo-
logical score (H-score) for each specimen was computed by
the formula:
H-score = proportion score × intensity score
A total score of 0 to 12 was calculated and graded as
negative (−, score: 0), weak (+, score: 1 to 4), moderate
(++, score: 5 to 8) or strong (+++, score: 9 to 12). The
Ki-67 LI was estimated as the percentage of Ki-67 posi-
tive cell nuclei by counting 500 to 1000 cells in thecation (adapted from [7])
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where the score difference was ≥2 for H-score and 10%
for LI, the slides were re-examined and a consensus was
reached by the observers. The mean score from each in-
dividual was calculated.
Statistical analysis
All statistical analyses were calculated using IBM SPSS
Statistics, version 19 (IBM, New York, USA). The IHC
scores from each observer were compared for interob-
server reliability using a two-way random effect model
with absolute agreement definition. The average measure
intraclass correlation coefficient (ICC) was obtained
from these results. The Pearson’s χ-square and Fisher’s
exact test were applied to examine the association
between biomarker expression and clinicopathological
variables. Spearman’s correlation coefficient was also cal-
culated when needed. A receiver operator characteristic
(ROC) was used to determine the best Ki-67 LI cut-off
point. Univariate analyses used the Kaplan-Meier esti-
mates, and were compared by the log-rank test. The
evaluation of independent factors for RFS was carried
out with the Cox proportional hazards model. P < 0.05
was indicative of statistical significance.
Ethics
The Regional Ethical Committees of the NJPH approved




The median age for the study cohort of 84 patients, 46
men and 38 women, was 61.5 years (range, 23 to
78 years), with 43 patients (51.2%) aged ≥60 years. Pri-
mary manifestations of GISTs were as follows: abdom-
inal distention or pain (n = 36), GI bleeding (n = 24),
obstruction (n = 6), tumor perforation or rupture (n = 3),
weight loss (n = 2), and incidental detection during im-
aging procedures or endoscopic screening (n = 13). The
GISTs were located in the stomach (n = 56), small intes-
tine (n = 20), colorectum (n = 5), and intraperitoneum
with unknown primary origin (n = 3). Resection was per-
formed by open laparotomy, except in 15 patients who
underwent laparoscopic resection. The tumor size varied
from 1.5 to 20 cm (median, 5.3 cm). Histologically, the
spindle cell type was most common (n = 63), followed by
epithelioid cell type (n = 13) and mixed type (n = 8). The
mitotic index, necrosis, and more detailed clinicopatho-
logical variables are summarized in Table 2.
Interobserver variability
Interobserver scoring agreement was tested for the two bio-
markers. The average measure ICCs were 0.93 for PTEN(95% confidence interval (CI), 0.89 to 0.96; P < 0.001) and
0.83 for Ki-67 LI (95% CI, 0.73-0.89; P < 0.001).
PTEN expression
The PTEN showed expression in the cytoplasm or in both
the cytoplasm and the nuclei of tumor cells in the major-
ity of cases, while pure nuclei staining was not observed.
According to the H-score scheme, PTEN expression was
considered as (−) in 11 patients (13.1%), (+) in 33 patients
(39.3%), (++) in 37 patients (44.0%), and (+++) in 3
patients (3.6%) (Figure 1A,B). There was a significant as-
sociation between PTEN expression and risk stratification
(P = 0.001), as indicated by Fisher’s exact test. Further-
more, Spearman’s correlation test revealed that PTEN ex-
pression was inversely correlated with risk stratification
(Rs = −0.318, P = 0.003) (Table 3).
Ki-67 LI
Ki-67 LI ranged from 0% to 23.4% (median, 1.1%)
(Figure 1C,D). The threshold value of Ki-67 LI was deter-
mined as 1% by ROC using relapse as basis, with a sen-
sitivity of 71.7% and specificity of 64.5% (area under the
curve, 0.651; 95% CI, 0.530 to 0.772; P = 0.021). Thirty-five
cases (41.7%) showed Ki-67 LI ≤1%, and 49 (58.3%)
showed Ki-67 LI >1%. There was a significant association
between Ki-67 LI >1% and risk stratification, as indicated
by Fisher’s exact test (P < 0.001) and Spearman’s corre-
lation test (Rs = 0.434, P < 0.001) (Table 3).
Follow-up
Follow-up data were available for all patients. The me-
dian follow-up time was 40.3 months (range, 4 to
97 months) for patients free of recurrence or metastasis,
and the cumulative 1, 3, and 5-year rates for RFS were
98.8%, 79.8%, and 70.2%, respectively. Twenty-five pa-
tients experienced tumor relapse during the follow-up
period, including local recurrence in the abdominopelvic
cavity (n = 16) and metastases to liver (n = 9). Metastasis
to the lymph nodes was not observed.
Univariate survival analysis
Univariate survival analysis demonstrated that GI bleed-
ing (P = 0.009), primary site (P = 0.001), tumor size (P =
0.022), mitotic index (P < 0.001), cellularity (P = 0.012),
tumor rupture (P = 0.013), modified NIH risk stratifica-
tion (P < 0.001), PTEN expression pattern (P = 0.036),
and Ki-67 LI (P = 0.043) were all significant prognostic
parameters for RFS. Correlations of clinicopathological
and immunohistochemical factors to RFS are shown in
Table 4 and Figure 2.
Multivariate survival analysis
Only those factors showing a significant correlation with
RFS in the univariate survival analysis were selected for









Range (median) 23 to 78 (61.5)
Clinical manifestation
Abdominal discomfort or pain 36 (42.9)
Gastrointestinal bleeding 24 (28.6)
Obstruction 6 (7.2)
Perforation or rupture 3 (3.6)




Small intestine 20 (23.8)
Colorectum 5 (6.0)
Intraperitoneally with unknown origin 3 (3.6)
Tumor size (cm)
≤5 41 (48.8)
5.1 to 10 34 (40.5)
>10 9 (10.7)





Mitotic index (per 50 high power fields)
0 to 5 53 (63.1)












Table 2 Clinicopathological characteristics in 84 patients
with primary GISTs (Continued)
Risk classification





Relapse-free survival 59 (70.2)
Recurrent 16 (19.1)
Metastasis 9 (10.7)
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wise forward and backward selection strategies. The
modified NIH risk stratification was excluded from the
multivariate analysis because it was based on tumor site,
size, mitotic index, and rupture, and markedly correlated
with each of these parameters. The results of the Cox re-
gression analysis are listed in Table 5. Gastrointestinal
bleeding (hazard ratio, 3.85; 95% CI, 1.63 to 9.10; P =
0.002), larger tumor size (P = 0.023), and high mitotic
index (P = 0.002) were statistically significant independ-
ent negative prognostic indicators for RFS.
Proposal for re-modifying GIST risk stratification system
Based on these results, we consider that the current
NIH consensus criteria could be further refined and ex-
panded by including GI bleeding as an important inde-
pendent prognostic indicator. For example, a patient
from the ‘low-risk’ group according to the modified NIH
consensus criteria who presented with GI bleeding pre-
operatively would be upgraded in risk to the re-modified
‘intermediate risk’ group. By such analogy, the risk classi-
fication could be reclassified into five groups: ‘very low’,
‘low’, ‘intermediate’, ‘high’, and ‘very high’. As shown in
Kaplan-Meier curves, this re-modified risk stratification
system demonstrated a better ability to predict prognosis
of primary resectable GISTs (P < 0.001) (Figure 2D,E).
Discussion
In this retrospective study based on follow-up data, we
have assessed the impact of a set of clinicopathological
parameters and the role of PTEN and Ki-67 on the prog-
nostic of primary GIST patients treated with surgery
alone. Our main findings were as follows: (1) GI bleed-
ing, a common manifestation for primary GISTs, was an
independent predictor of worse prognosis for RFS; (2)
the IHC underexpression of PTEN was associated with
worse RFS at univariate analysis; (3) a Ki-67 LI >1% was
associated with worse RFS at univariate analysis; (4) GI
bleeding could be considered an additional prognostic
indicator in the GIST risk classification scheme.
Figure 1 IHC analysis of GISTs representing different expression of PTEN and Ki-67 (3,3′-Diaminobenzidine, magnification × 20).
(A) PTEN, cytoplasmic staining (H-score, 4) and (B) both cytoplasmic and nuclei staining (H-score, 8). (C) Ki-67 nuclei staining in 5% and (D) 20%
of tumor cells.
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clinical symptoms of GIST [16]. In a long-term follow-up
of 1,765 cases of gastric GISTs [17], 54.5% patients pre-
sented with GI bleeding, ranging from chronic insidious
hemorrhage with or without anemia to acute melena or
hematemesis. Although we could not reproduce this high
incidence, our data still illustrate an incidence of GI bleed-
ing as high as 28.6%. Ulceration and mucosal invasion are
the most common causes. Ulceration of the mucosa is
commonly manifest in GISTs (39.6%), and is a statistically
significant predictor for progressive disease (P < 0.0003)
[16]. Although mucosal invasion is rare, it has been shownTable 3 Correlation between the expression of PTEN, Ki-67 an
Risk classification number (%
Very low Low Intermediat
PTEN
(−) 2 (2.4) 3 (3.6) 1 (1.2)
(+) – 4 (4.8) 7 (8.3)
(++) 3 (3.6) 17 (20.2) 8 (9.5)
(+++) – 2 (2.4) 1 (1.2)
Ki-67 labeling index
≤1% 5 (6.0) 15 (17.9) 8 (9.5)
>1% – 11 (13.1) 9 (10.7)
*Fisher’s exact test.in a surprisingly high proportion of progressive GISTs (22
of 24 cases) [18]. Research regarding the prognostic
implication of GI bleeding on RFS in GISTs is scant; in
addition to one study [19] that found a statistical significant
prediction value on univariate analysis but not on multivari-
ate analysis. Our data demonstrated that GI bleeding was
an independent predictor of poor prognosis for RFS. As
shown in Figure 2E, the curves of the ‘very low’ and ‘low’
groups merged totally, which might suggest that these two
groups in our proposal risk classification system can be in-
corporated into the same group. In that case, there would
still be four groups, while the ‘very high’ group highlightsd risk grade in 84 GISTs
) P Spearman’s correlation









Table 4 Univariate analysis of factors influencing RFS
Factors 5-year RFS rate (%) P
Sex Male: female 59.6:59.5 0.702
Age (years) ≤60: >60 54.6:64.3 0.306
Gastrointestinal bleeding Yes: no 36.4:71.9 0.009
Primary tumor site Gastric: non-gastric 73.1:36.0 0.001
Tumor size (cm) ≤5: 5.1 to 10: >10 79.9:47.0:33.3 0.022
Predominant cell type Spindle: epithelioid: mixed 63.0:45.0:51.4 0.423
Mitotic index (per 50 high power fields) 0 to 5: 5.1 to 10: >10 74.9:46.1:22.2 <0.001
Cellularity Paucicellular or moderate: high 69.6: 50.2 0.012
Necrosis Yes: no 48.9: 69.2 0.09
Tumor rupture Yes: no 20.0: 63.3 0.013
Risk classification Very low: low: intermediate: high 100.0:91.7:60.4:36.0 <0.001
PTEN (−): (+): (++): (+++) 36.4:49.8:70.7:100.0 0.036
Ki-67 labeling index ≤1%: >1% 79.0:48.5 0.043
PTEN, Phosphatase and tensin homolog deleted from chromosome 10.
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Moreover, Kaplan-Meier curves illustrated that patients
whose risk category upgraded due to GI bleeding in our re-
modified risk stratification scheme are more likely to suffer
from disease relapse, suggesting that GI bleeding, a clinical
feature worth recording, might be added to the risk classifi-
cation system in further studies.
Original researches performed in murine models, sug-
gesting that PTEN might be involved in the aberrant activa-
tion of cell signaling transduction in GISTs tumorigenesis;
however, the results are inconsistent. By using a KitK641E
knock-in mouse model of GIST, Deneubourg et al. [20] in-
dicated that the upregulation of PTEN might act as a nega-
tive feedback mechanism to limit PI3-kinase activation
downstream of Kit in a context of oncogenic mutation. On
the other hand, in a panel of GIST xenograft mouse models,
Floris and colleagues [21] illustrated that homozygous PTEN
loss was identified in the GIST-PSW (GIST biopsy tumor
cell with KIT exon 11 mutation) and GIST882Ly (GIST cell
line harboring homozygous KIT exon 13 mutation) xeno-
grafts, while heterozygous PTEN loss was observed in a
GIST48 (GIST cell line carrying both KIT exon 11 and 17
mutation) xenograft. Importantly, they also confirmed the
lack of PTEN protein expression in the GIST-PSW and
GIST882Ly xenografts. PTEN protein expression has previ-
ously been investigated in clinical GISTs tissue samples by
IHC, and a clear relationship between low or absent PTEN
expression and poor prognosis was revealed, either alone or
in combination with other biomarkers [22,23]. Our study,
adopting a PTEN IHC H-score method, provides further
support for the role of absent or low expression (H-score, 0
to 4) of PTEN (in 52.4% GISTs) as a predictor of recurrence
in patients with primary GIST, although the result was not
statistically significant on multivariate analysis.Additionally, diffuse cytoplasmic or both cytoplasmic
and nucleic PTEN immunostaining was observed, while
pure nuclei staining was not observed in this study.
However, exclusively nuclear PTEN immunoreactivity in
GIST was previously reported in two studies [22,23]. A
possible reason for this discrepancy could be the differ-
ent anti-PTEN antibodies used in IHC analysis. Our
findings are consistent with Deneubourg and his col-
leagues, who revealed PTEN subcellular expression in
the cytoplasm and partly in the nucleus by immuno-
fluorescence in human GIST882 cells [20]. PTEN has
been shown to shuttle between the cytoplasm and nu-
cleus. Its different subcellular localization might imply
different molecular functions. It is worth noting that
negative nuclear PTEN immunostaining, unlike cyto-
plasmic PTEN expression, is an independent prognostic
factor for survival in esophageal squamous cell carcin-
oma [24]. Accordingly, further studies are warranted, to
define the prognostic implication of different subcellular
PTEN expression in GISTs.
Although Ki-67 shows the most potential as a prog-
nostic indicator for GISTs in the literature, the exact
threshold value of Ki-67 LI for malignant predicting re-
mains debatable. In documented research, different cut-
off points have been suggested: 0.82% [25], 2.7% [26], 3%
[27], 5% [15,23], 6% [28], or 10% [29]; however few of
these cut-off points were established based on ROC ana-
lysis. In our series, a 1% LI was confirmed as the best
threshold value for relapse in ROC analysis, with 71.7%
sensitivity and 64.5% specificity. Whether Ki-67 LI could
replace mitotic counting in prognostication remains
controversial [30]. Some scholars hold that the mitotic
index reflects the M stage of mitosis only; but, because
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Modified NIH consensus criteria
Very low, n = 5
Low, n = 26
Intermediate, n = 17
High, n = 36
log rank P < 0.001
D
Figure 2 Relapse-free survival analysis of 84 patients with primary GISTs. Kaplan-Meier curve analysis demonstrated a worse relapse-free
survival for patients presenting with (A) gastrointestinal (GI) bleeding, (B) absent or low PTEN expression, and (C) Ki-67 > 1%. By including GI
bleeding as an independent prognostic indicator, our re-modified risk stratification system (E) showed a better ability to predict recurrence in
primary GISTs than modified NIH consensus criteria (D).
Wang et al. World Journal of Surgical Oncology 2014, 12:89 Page 8 of 10
http://www.wjso.com/content/12/1/89
Table 5 Results of Cox regression analysis (stepwise
forward method) summarizing significant independent








Yes 3.85 1.63 to 9.10 0.002
Tumor size 0.023*
≤5 cm 1.00
5.1 to 10 cm 1.86 0.67 to 5.15 0.232
>10 cm 6.71 1.70 to 26.51 0.007
Mitotic index 0.002*
0 to 5 (per 50 high power fields) 1.00
5.1 to 10 (per 50 high power fields) 5.72 2.09 to 15.64 0.001
>10 (per 50 high power fields) 3.44 1.13 to 10.45 0.029
*Overall significance as a prognostic factor.
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ered to be more appropriate as an objective index of the
malignancy of GISTs [31]. Molenaar et al. [32] also dem-
onstrated higher observer reliability of Ki-67 than mi-
totic counting in assessment of mitotic activity. On the
contrary, Wong et al. [15] advocated Ki67 LI to be infer-
ior to mitotic index as a prognostic marker. Our study
shows that a Ki-67 LI level higher than 1% is associated
with a higher relapse potential of primary GISTs, on uni-
variate survival analysis but not on multivariate analysis,
and that mitotic index remains a stable prognostic indi-
cator, on both univariate and multivariate analysis. We
propose that if the mitotic index is based on counting,
fewer than 50 high power fields (that is in a small biopsy
sample), Ki-67 immunohistochemical analysis could be
an alternative for mitotic index.
The NIH consensus criteria [5], AFIP criteria [6], and
modified NIH consensus criteria [7] are frequently used
to estimate the risk of recurrence after surgery in GIST,
and their prognostic accuracy is generally similar [33].
NIH consensus criteria stratify risk based on tumor size
and mitotic counting, whereas AFIP criteria also include
tumor site. Modified NIH criteria encompass four fac-
tors: tumor size, mitotic index, site, and tumor rupture,
which have been well established as important independ-
ent prognostic factors for GIST recurrence [34,35]
(Table 1). Our data regarding these parameters reach a
general agreement with prior reports, showing that
larger tumor size and high mitotic index are steadily in-
dicative of poor RFS for primary GISTs, in addition to
tumor site and rupture, which were not identified as
independent prognostic factors in multivariate analysis.
In a pooled analysis of ten population-based seriesincluding 2,459 GIST patients treated with surgery alone
[33], the estimated 5-year and 15-year RFS rates were
70.5% and 59.9%, respectively. In line with this study,
the overall outcome after surgery in our cohort was pre-
sented as 1, 3, and 5-year RFS rates (98.8%, 79.8%, and
70.2%, respectively).
There are certain limitations in our study. First, this is
a retrospective study with a limited sample size of study
population and a large proportion of censored cases.
Secondly, the study was conducted in one single tertiary
hospital. Thus, a larger scale, multicenter prospective
study with longer-term follow-up investigation is war-
ranted. Finally, the inability of TMA approach to detect
all information of tumor samples might cause bias [36].
Despite these caveats, it appears that our findings can
contribute to the knowledge of prognostic biomarkers in
patients with primary GISTs who are treated with sur-
gery alone.
Conclusions
The current NIH consensus criteria remain a stable and
practical predicting tool in primary GISTs risk classification.
We found that GI bleeding was an independent prognostic
indicator for poor RFS in patients with primary GISTs
treated with surgery alone. We proposed that the current
NIH consensus criteria could be improved by including this
important clinical manifestation. Whether absent or low ex-
pression of PTEN, and Ki-67 LI higher than 1% could add
independently to the prognostication of GISTs should be
further investigated in a larger series.
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